Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis

Delphine Javelaud, Khalid Mohammad, Christopher R. McKenna, Pierrick Fournier, Flavie Luciani, Maryla Niewolna, Jocelyne André, Véronique Delmas, Lionel Larue, Theresa Guise, Alain Mauviel

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

Melanoma has a propensity to metastasize to bone, where it is exposed to high concentrations of transforming growth factor-β (TGF-β). Because TGF-β promotes bone metastases from other solid tumors, such as breast cancer, we tested the role of TGF-β in melanoma metastases to bone. 1205Lu melanoma cells, stably transfected to overexpress the natural TGF-β/Smad signaling inhibitor Smad7, were studied in an experimental model of bone metastasis whereby tumor cells are inoculated into the left cardiac ventricle of nude mice. All mice bearing parental and mock-transfected 1205Lu cells developed osteolytic bone metastases 5 weeks post-tumor inoculation. Mice bearing 1205Lu-Smad7 tumors had significantly less osteolysis on radiographs and longer survival compared with parental and mock-transfected 1205Lu mice. To determine if the reduced bone metastases observed in mice bearing 1205Lu-Smad7 clones was due to reduced expression of TGF-β target genes known to enhance metastases to bone from breast cancer cells, we analyzed gene expression of osteolytic factors, parathyroid hormone-related protein (PTHrP) and interleukin-11 (IL-11), the chemotactic receptor CXCR4, and osteopontin in 1205Lu cells. Quantitative reverse transcription-PCR analysis indicated that PTHrP, IL-11, CXCR4, and osteopontin mRNA steady-state levels were robustly increased in response to TGF-β and that Smad7 and the TβRI small-molecule inhibitor, SB431542, prevented such induction. In addition, 1205Lu-Smad7 bone metastases expressed significantly lower levels of IL-11, connective tissue growth factor, and PTHrP. These data suggest that TGF-β promotes osteolytic bone metastases due to melanoma by stimulating the expression of prometastatic factors via the Smad pathway. Blockade of TGF-β signaling may be an effective treatment for melanoma metastasis to bone.

Original languageEnglish (US)
Pages (from-to)2317-2324
Number of pages8
JournalCancer Research
Volume67
Issue number5
DOIs
StatePublished - Mar 1 2007
Externally publishedYes

Fingerprint

Transforming Growth Factors
Melanoma
Neoplasm Metastasis
Bone and Bones
Parathyroid Hormone-Related Protein
Interleukin-11
Osteopontin
Heart Ventricles
Interleukin-11 Receptors
Neoplasms
Breast Neoplasms
Connective Tissue Growth Factor
Bone Neoplasms
Osteolysis
Nude Mice
Growth Hormone
Reverse Transcription
Theoretical Models
Clone Cells
Gene Expression

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Javelaud, D., Mohammad, K., McKenna, C. R., Fournier, P., Luciani, F., Niewolna, M., ... Mauviel, A. (2007). Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Research, 67(5), 2317-2324. https://doi.org/10.1158/0008-5472.CAN-06-3950

Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. / Javelaud, Delphine; Mohammad, Khalid; McKenna, Christopher R.; Fournier, Pierrick; Luciani, Flavie; Niewolna, Maryla; André, Jocelyne; Delmas, Véronique; Larue, Lionel; Guise, Theresa; Mauviel, Alain.

In: Cancer Research, Vol. 67, No. 5, 01.03.2007, p. 2317-2324.

Research output: Contribution to journalArticle

Javelaud, D, Mohammad, K, McKenna, CR, Fournier, P, Luciani, F, Niewolna, M, André, J, Delmas, V, Larue, L, Guise, T & Mauviel, A 2007, 'Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis', Cancer Research, vol. 67, no. 5, pp. 2317-2324. https://doi.org/10.1158/0008-5472.CAN-06-3950
Javelaud, Delphine ; Mohammad, Khalid ; McKenna, Christopher R. ; Fournier, Pierrick ; Luciani, Flavie ; Niewolna, Maryla ; André, Jocelyne ; Delmas, Véronique ; Larue, Lionel ; Guise, Theresa ; Mauviel, Alain. / Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. In: Cancer Research. 2007 ; Vol. 67, No. 5. pp. 2317-2324.
@article{e733b23eff7a455fa6acde5a13e35f2d,
title = "Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis",
abstract = "Melanoma has a propensity to metastasize to bone, where it is exposed to high concentrations of transforming growth factor-β (TGF-β). Because TGF-β promotes bone metastases from other solid tumors, such as breast cancer, we tested the role of TGF-β in melanoma metastases to bone. 1205Lu melanoma cells, stably transfected to overexpress the natural TGF-β/Smad signaling inhibitor Smad7, were studied in an experimental model of bone metastasis whereby tumor cells are inoculated into the left cardiac ventricle of nude mice. All mice bearing parental and mock-transfected 1205Lu cells developed osteolytic bone metastases 5 weeks post-tumor inoculation. Mice bearing 1205Lu-Smad7 tumors had significantly less osteolysis on radiographs and longer survival compared with parental and mock-transfected 1205Lu mice. To determine if the reduced bone metastases observed in mice bearing 1205Lu-Smad7 clones was due to reduced expression of TGF-β target genes known to enhance metastases to bone from breast cancer cells, we analyzed gene expression of osteolytic factors, parathyroid hormone-related protein (PTHrP) and interleukin-11 (IL-11), the chemotactic receptor CXCR4, and osteopontin in 1205Lu cells. Quantitative reverse transcription-PCR analysis indicated that PTHrP, IL-11, CXCR4, and osteopontin mRNA steady-state levels were robustly increased in response to TGF-β and that Smad7 and the TβRI small-molecule inhibitor, SB431542, prevented such induction. In addition, 1205Lu-Smad7 bone metastases expressed significantly lower levels of IL-11, connective tissue growth factor, and PTHrP. These data suggest that TGF-β promotes osteolytic bone metastases due to melanoma by stimulating the expression of prometastatic factors via the Smad pathway. Blockade of TGF-β signaling may be an effective treatment for melanoma metastasis to bone.",
author = "Delphine Javelaud and Khalid Mohammad and McKenna, {Christopher R.} and Pierrick Fournier and Flavie Luciani and Maryla Niewolna and Jocelyne Andr{\'e} and V{\'e}ronique Delmas and Lionel Larue and Theresa Guise and Alain Mauviel",
year = "2007",
month = "3",
day = "1",
doi = "10.1158/0008-5472.CAN-06-3950",
language = "English (US)",
volume = "67",
pages = "2317--2324",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis

AU - Javelaud, Delphine

AU - Mohammad, Khalid

AU - McKenna, Christopher R.

AU - Fournier, Pierrick

AU - Luciani, Flavie

AU - Niewolna, Maryla

AU - André, Jocelyne

AU - Delmas, Véronique

AU - Larue, Lionel

AU - Guise, Theresa

AU - Mauviel, Alain

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Melanoma has a propensity to metastasize to bone, where it is exposed to high concentrations of transforming growth factor-β (TGF-β). Because TGF-β promotes bone metastases from other solid tumors, such as breast cancer, we tested the role of TGF-β in melanoma metastases to bone. 1205Lu melanoma cells, stably transfected to overexpress the natural TGF-β/Smad signaling inhibitor Smad7, were studied in an experimental model of bone metastasis whereby tumor cells are inoculated into the left cardiac ventricle of nude mice. All mice bearing parental and mock-transfected 1205Lu cells developed osteolytic bone metastases 5 weeks post-tumor inoculation. Mice bearing 1205Lu-Smad7 tumors had significantly less osteolysis on radiographs and longer survival compared with parental and mock-transfected 1205Lu mice. To determine if the reduced bone metastases observed in mice bearing 1205Lu-Smad7 clones was due to reduced expression of TGF-β target genes known to enhance metastases to bone from breast cancer cells, we analyzed gene expression of osteolytic factors, parathyroid hormone-related protein (PTHrP) and interleukin-11 (IL-11), the chemotactic receptor CXCR4, and osteopontin in 1205Lu cells. Quantitative reverse transcription-PCR analysis indicated that PTHrP, IL-11, CXCR4, and osteopontin mRNA steady-state levels were robustly increased in response to TGF-β and that Smad7 and the TβRI small-molecule inhibitor, SB431542, prevented such induction. In addition, 1205Lu-Smad7 bone metastases expressed significantly lower levels of IL-11, connective tissue growth factor, and PTHrP. These data suggest that TGF-β promotes osteolytic bone metastases due to melanoma by stimulating the expression of prometastatic factors via the Smad pathway. Blockade of TGF-β signaling may be an effective treatment for melanoma metastasis to bone.

AB - Melanoma has a propensity to metastasize to bone, where it is exposed to high concentrations of transforming growth factor-β (TGF-β). Because TGF-β promotes bone metastases from other solid tumors, such as breast cancer, we tested the role of TGF-β in melanoma metastases to bone. 1205Lu melanoma cells, stably transfected to overexpress the natural TGF-β/Smad signaling inhibitor Smad7, were studied in an experimental model of bone metastasis whereby tumor cells are inoculated into the left cardiac ventricle of nude mice. All mice bearing parental and mock-transfected 1205Lu cells developed osteolytic bone metastases 5 weeks post-tumor inoculation. Mice bearing 1205Lu-Smad7 tumors had significantly less osteolysis on radiographs and longer survival compared with parental and mock-transfected 1205Lu mice. To determine if the reduced bone metastases observed in mice bearing 1205Lu-Smad7 clones was due to reduced expression of TGF-β target genes known to enhance metastases to bone from breast cancer cells, we analyzed gene expression of osteolytic factors, parathyroid hormone-related protein (PTHrP) and interleukin-11 (IL-11), the chemotactic receptor CXCR4, and osteopontin in 1205Lu cells. Quantitative reverse transcription-PCR analysis indicated that PTHrP, IL-11, CXCR4, and osteopontin mRNA steady-state levels were robustly increased in response to TGF-β and that Smad7 and the TβRI small-molecule inhibitor, SB431542, prevented such induction. In addition, 1205Lu-Smad7 bone metastases expressed significantly lower levels of IL-11, connective tissue growth factor, and PTHrP. These data suggest that TGF-β promotes osteolytic bone metastases due to melanoma by stimulating the expression of prometastatic factors via the Smad pathway. Blockade of TGF-β signaling may be an effective treatment for melanoma metastasis to bone.

UR - http://www.scopus.com/inward/record.url?scp=33947265488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947265488&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-3950

DO - 10.1158/0008-5472.CAN-06-3950

M3 - Article

VL - 67

SP - 2317

EP - 2324

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 5

ER -